CN113476600A - Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 - Google Patents
Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 Download PDFInfo
- Publication number
- CN113476600A CN113476600A CN202110779345.1A CN202110779345A CN113476600A CN 113476600 A CN113476600 A CN 113476600A CN 202110779345 A CN202110779345 A CN 202110779345A CN 113476600 A CN113476600 A CN 113476600A
- Authority
- CN
- China
- Prior art keywords
- vaccine
- avc
- antigen
- adjuvant
- immunogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 229960005486 vaccine Drugs 0.000 title claims abstract description 42
- 229940124931 vaccine adjuvant Drugs 0.000 title claims abstract description 24
- 239000012646 vaccine adjuvant Substances 0.000 title claims abstract description 24
- 239000002671 adjuvant Substances 0.000 title abstract description 60
- 230000002163 immunogen Effects 0.000 claims abstract description 30
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 102000036639 antigens Human genes 0.000 claims description 65
- 239000000427 antigen Substances 0.000 claims description 64
- 108091007433 antigens Proteins 0.000 claims description 64
- 210000004027 cell Anatomy 0.000 claims description 34
- 230000028993 immune response Effects 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 16
- 241001678559 COVID-19 virus Species 0.000 claims description 15
- 241000700605 Viruses Species 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 244000052769 pathogen Species 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 5
- 241000711573 Coronaviridae Species 0.000 claims description 5
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 239000002504 physiological saline solution Substances 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 229940031551 inactivated vaccine Drugs 0.000 claims description 4
- 230000015788 innate immune response Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 208000025721 COVID-19 Diseases 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229940098458 powder spray Drugs 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 229940124551 recombinant vaccine Drugs 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 239000006190 sub-lingual tablet Substances 0.000 claims description 2
- 229940098466 sublingual tablet Drugs 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940021993 prophylactic vaccine Drugs 0.000 claims 1
- 229940021747 therapeutic vaccine Drugs 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 abstract description 14
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract description 12
- 230000024932 T cell mediated immunity Effects 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000016784 immunoglobulin production Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000003472 neutralizing effect Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 7
- 230000036755 cellular response Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- -1 small molecule compound Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 229940022962 COVID-19 vaccine Drugs 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000743 Interleukin-5 Human genes 0.000 description 4
- 108010002616 Interleukin-5 Proteins 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- LXMKTIZAGIBQRX-HRCADAONSA-N Arg-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O LXMKTIZAGIBQRX-HRCADAONSA-N 0.000 description 2
- IBLAOXSULLECQZ-IUKAMOBKSA-N Asn-Ile-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CC(N)=O IBLAOXSULLECQZ-IUKAMOBKSA-N 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- WUHBLPVELFTPQK-KKUMJFAQSA-N Leu-Tyr-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O WUHBLPVELFTPQK-KKUMJFAQSA-N 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 241000223810 Plasmodium vivax Species 0.000 description 2
- 241000233872 Pneumocystis carinii Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241001116459 Sequoia Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241000223997 Toxoplasma gondii Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- BTWMICVCQLKKNR-DCAQKATOSA-N Val-Leu-Ser Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C([O-])=O BTWMICVCQLKKNR-DCAQKATOSA-N 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 2
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 108010037850 glycylvaline Proteins 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229940126583 recombinant protein vaccine Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- CWFMWBHMIMNZLN-NAKRPEOUSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carboxylic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CWFMWBHMIMNZLN-NAKRPEOUSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 1
- KUDREHRZRIVKHS-UWJYBYFXSA-N Ala-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KUDREHRZRIVKHS-UWJYBYFXSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 1
- VRTOMXFZHGWHIJ-KZVJFYERSA-N Ala-Thr-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VRTOMXFZHGWHIJ-KZVJFYERSA-N 0.000 description 1
- IETUUAHKCHOQHP-KZVJFYERSA-N Ala-Thr-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)[C@@H](C)O)C(O)=O IETUUAHKCHOQHP-KZVJFYERSA-N 0.000 description 1
- XMIAMUXIMWREBJ-HERUPUMHSA-N Ala-Trp-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)O)N XMIAMUXIMWREBJ-HERUPUMHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- JSHVMZANPXCDTL-GMOBBJLQSA-N Arg-Asp-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JSHVMZANPXCDTL-GMOBBJLQSA-N 0.000 description 1
- JCAISGGAOQXEHJ-ZPFDUUQYSA-N Arg-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N JCAISGGAOQXEHJ-ZPFDUUQYSA-N 0.000 description 1
- GXXWTNKNFFKTJB-NAKRPEOUSA-N Arg-Ile-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O GXXWTNKNFFKTJB-NAKRPEOUSA-N 0.000 description 1
- CZUHPNLXLWMYMG-UBHSHLNASA-N Arg-Phe-Ala Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C)C(O)=O)CC1=CC=CC=C1 CZUHPNLXLWMYMG-UBHSHLNASA-N 0.000 description 1
- LLQIAIUAKGNOSE-NHCYSSNCSA-N Arg-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N LLQIAIUAKGNOSE-NHCYSSNCSA-N 0.000 description 1
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 1
- DQTIWTULBGLJBL-DCAQKATOSA-N Asn-Arg-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N DQTIWTULBGLJBL-DCAQKATOSA-N 0.000 description 1
- DAPLJWATMAXPPZ-CIUDSAMLSA-N Asn-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O DAPLJWATMAXPPZ-CIUDSAMLSA-N 0.000 description 1
- UGXVKHRDGLYFKR-CIUDSAMLSA-N Asn-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(N)=O UGXVKHRDGLYFKR-CIUDSAMLSA-N 0.000 description 1
- CZIXHXIJJZLYRJ-SRVKXCTJSA-N Asn-Cys-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CZIXHXIJJZLYRJ-SRVKXCTJSA-N 0.000 description 1
- SQZIAWGBBUSSPJ-ZKWXMUAHSA-N Asn-Cys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N SQZIAWGBBUSSPJ-ZKWXMUAHSA-N 0.000 description 1
- OOWSBIOUKIUWLO-RCOVLWMOSA-N Asn-Gly-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O OOWSBIOUKIUWLO-RCOVLWMOSA-N 0.000 description 1
- BXUHCIXDSWRSBS-CIUDSAMLSA-N Asn-Leu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O BXUHCIXDSWRSBS-CIUDSAMLSA-N 0.000 description 1
- UHGUKCOQUNPSKK-CIUDSAMLSA-N Asn-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N UHGUKCOQUNPSKK-CIUDSAMLSA-N 0.000 description 1
- NCFJQJRLQJEECD-NHCYSSNCSA-N Asn-Leu-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O NCFJQJRLQJEECD-NHCYSSNCSA-N 0.000 description 1
- ALHMNHZJBYBYHS-DCAQKATOSA-N Asn-Lys-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O ALHMNHZJBYBYHS-DCAQKATOSA-N 0.000 description 1
- REQUGIWGOGSOEZ-ZLUOBGJFSA-N Asn-Ser-Asn Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)C(=O)N REQUGIWGOGSOEZ-ZLUOBGJFSA-N 0.000 description 1
- RTFXPCYMDYBZNQ-SRVKXCTJSA-N Asn-Tyr-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O RTFXPCYMDYBZNQ-SRVKXCTJSA-N 0.000 description 1
- DATSKXOXPUAOLK-KKUMJFAQSA-N Asn-Tyr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O DATSKXOXPUAOLK-KKUMJFAQSA-N 0.000 description 1
- HBUJSDCLZCXXCW-YDHLFZDLSA-N Asn-Val-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HBUJSDCLZCXXCW-YDHLFZDLSA-N 0.000 description 1
- SVFOIXMRMLROHO-SRVKXCTJSA-N Asp-Asp-Phe Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SVFOIXMRMLROHO-SRVKXCTJSA-N 0.000 description 1
- YDJVIBMKAMQPPP-LAEOZQHASA-N Asp-Glu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O YDJVIBMKAMQPPP-LAEOZQHASA-N 0.000 description 1
- AITKTFCQOBRJTG-CIUDSAMLSA-N Asp-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N AITKTFCQOBRJTG-CIUDSAMLSA-N 0.000 description 1
- VNXQRBXEQXLERQ-CIUDSAMLSA-N Asp-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N VNXQRBXEQXLERQ-CIUDSAMLSA-N 0.000 description 1
- NJLLRXWFPQQPHV-SRVKXCTJSA-N Asp-Tyr-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O NJLLRXWFPQQPHV-SRVKXCTJSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241001185363 Chlamydiae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- OIMUAKUQOUEPCZ-WHFBIAKZSA-N Cys-Asn-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIMUAKUQOUEPCZ-WHFBIAKZSA-N 0.000 description 1
- SKSJPIBFNFPTJB-NKWVEPMBSA-N Cys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CS)N)C(=O)O SKSJPIBFNFPTJB-NKWVEPMBSA-N 0.000 description 1
- QQOWCDCBFFBRQH-IXOXFDKPSA-N Cys-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CS)N)O QQOWCDCBFFBRQH-IXOXFDKPSA-N 0.000 description 1
- HPZAJRPYUIHDIN-BZSNNMDCSA-N Cys-Tyr-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CS)N HPZAJRPYUIHDIN-BZSNNMDCSA-N 0.000 description 1
- NGOIQDYZMIKCOK-NAKRPEOUSA-N Cys-Val-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NGOIQDYZMIKCOK-NAKRPEOUSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- HHWQMFIGMMOVFK-WDSKDSINSA-N Gln-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O HHWQMFIGMMOVFK-WDSKDSINSA-N 0.000 description 1
- UWMDGPFFTKDUIY-HJGDQZAQSA-N Gln-Pro-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWMDGPFFTKDUIY-HJGDQZAQSA-N 0.000 description 1
- DCWNCMRZIZSZBL-KKUMJFAQSA-N Gln-Pro-Tyr Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)N)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O DCWNCMRZIZSZBL-KKUMJFAQSA-N 0.000 description 1
- GHAXJVNBAKGWEJ-AVGNSLFASA-N Gln-Ser-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GHAXJVNBAKGWEJ-AVGNSLFASA-N 0.000 description 1
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 description 1
- KRRFFAHEAOCBCQ-SIUGBPQLSA-N Glu-Ile-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KRRFFAHEAOCBCQ-SIUGBPQLSA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- SYAYROHMAIHWFB-KBIXCLLPSA-N Glu-Ser-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SYAYROHMAIHWFB-KBIXCLLPSA-N 0.000 description 1
- FVGOGEGGQLNZGH-DZKIICNBSA-N Glu-Val-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FVGOGEGGQLNZGH-DZKIICNBSA-N 0.000 description 1
- LURCIJSJAKFCRO-QWRGUYRKSA-N Gly-Asn-Tyr Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LURCIJSJAKFCRO-QWRGUYRKSA-N 0.000 description 1
- QSTLUOIOYLYLLF-WDSKDSINSA-N Gly-Asp-Glu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O QSTLUOIOYLYLLF-WDSKDSINSA-N 0.000 description 1
- PEZZSFLFXXFUQD-XPUUQOCRSA-N Gly-Cys-Val Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O PEZZSFLFXXFUQD-XPUUQOCRSA-N 0.000 description 1
- NPSWCZIRBAYNSB-JHEQGTHGSA-N Gly-Gln-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NPSWCZIRBAYNSB-JHEQGTHGSA-N 0.000 description 1
- PTIIBFKSLCYQBO-NHCYSSNCSA-N Gly-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)CN PTIIBFKSLCYQBO-NHCYSSNCSA-N 0.000 description 1
- MTBIKIMYHUWBRX-QWRGUYRKSA-N Gly-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN MTBIKIMYHUWBRX-QWRGUYRKSA-N 0.000 description 1
- YYXJFBMCOUSYSF-RYUDHWBXSA-N Gly-Phe-Gln Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYXJFBMCOUSYSF-RYUDHWBXSA-N 0.000 description 1
- NWOSHVVPKDQKKT-RYUDHWBXSA-N Gly-Tyr-Gln Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O NWOSHVVPKDQKKT-RYUDHWBXSA-N 0.000 description 1
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 1
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- HTZKFIYQMHJWSQ-INTQDDNPSA-N His-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N HTZKFIYQMHJWSQ-INTQDDNPSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- VSZALHITQINTGC-GHCJXIJMSA-N Ile-Ala-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VSZALHITQINTGC-GHCJXIJMSA-N 0.000 description 1
- WZPIKDWQVRTATP-SYWGBEHUSA-N Ile-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(O)=O)=CNC2=C1 WZPIKDWQVRTATP-SYWGBEHUSA-N 0.000 description 1
- QLRMMMQNCWBNPQ-QXEWZRGKSA-N Ile-Arg-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)O)N QLRMMMQNCWBNPQ-QXEWZRGKSA-N 0.000 description 1
- RQJUKVXWAKJDBW-SVSWQMSJSA-N Ile-Ser-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N RQJUKVXWAKJDBW-SVSWQMSJSA-N 0.000 description 1
- GNXGAVNTVNOCLL-SIUGBPQLSA-N Ile-Tyr-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N GNXGAVNTVNOCLL-SIUGBPQLSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- HUEBCHPSXSQUGN-GARJFASQSA-N Leu-Cys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N HUEBCHPSXSQUGN-GARJFASQSA-N 0.000 description 1
- PBGDOSARRIJMEV-DLOVCJGASA-N Leu-His-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(O)=O PBGDOSARRIJMEV-DLOVCJGASA-N 0.000 description 1
- RTIRBWJPYJYTLO-MELADBBJSA-N Leu-Lys-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N RTIRBWJPYJYTLO-MELADBBJSA-N 0.000 description 1
- GCXGCIYIHXSKAY-ULQDDVLXSA-N Leu-Phe-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GCXGCIYIHXSKAY-ULQDDVLXSA-N 0.000 description 1
- UCRJTSIIAYHOHE-ULQDDVLXSA-N Leu-Tyr-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UCRJTSIIAYHOHE-ULQDDVLXSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- VHNOAIFVYUQOOY-XUXIUFHCSA-N Lys-Arg-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VHNOAIFVYUQOOY-XUXIUFHCSA-N 0.000 description 1
- ZQCVMVCVPFYXHZ-SRVKXCTJSA-N Lys-Asn-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCCN ZQCVMVCVPFYXHZ-SRVKXCTJSA-N 0.000 description 1
- DZQYZKPINJLLEN-KKUMJFAQSA-N Lys-Cys-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N)O DZQYZKPINJLLEN-KKUMJFAQSA-N 0.000 description 1
- NJNRBRKHOWSGMN-SRVKXCTJSA-N Lys-Leu-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O NJNRBRKHOWSGMN-SRVKXCTJSA-N 0.000 description 1
- YPLVCBKEPJPBDQ-MELADBBJSA-N Lys-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N YPLVCBKEPJPBDQ-MELADBBJSA-N 0.000 description 1
- YDDDRTIPNTWGIG-SRVKXCTJSA-N Lys-Lys-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O YDDDRTIPNTWGIG-SRVKXCTJSA-N 0.000 description 1
- GHKXHCMRAUYLBS-CIUDSAMLSA-N Lys-Ser-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O GHKXHCMRAUYLBS-CIUDSAMLSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- UHRNIXJAGGLKHP-DLOVCJGASA-N Phe-Ala-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O UHRNIXJAGGLKHP-DLOVCJGASA-N 0.000 description 1
- YYRCPTVAPLQRNC-ULQDDVLXSA-N Phe-Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC1=CC=CC=C1 YYRCPTVAPLQRNC-ULQDDVLXSA-N 0.000 description 1
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 1
- KJJROSNFBRWPHS-JYJNAYRXSA-N Phe-Glu-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KJJROSNFBRWPHS-JYJNAYRXSA-N 0.000 description 1
- ZLGQEBCCANLYRA-RYUDHWBXSA-N Phe-Gly-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O ZLGQEBCCANLYRA-RYUDHWBXSA-N 0.000 description 1
- CJAHQEZWDZNSJO-KKUMJFAQSA-N Phe-Lys-Cys Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 CJAHQEZWDZNSJO-KKUMJFAQSA-N 0.000 description 1
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 1
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 1
- JHSRGEODDALISP-XVSYOHENSA-N Phe-Thr-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O JHSRGEODDALISP-XVSYOHENSA-N 0.000 description 1
- BSKMOCNNLNDIMU-CDMKHQONSA-N Phe-Thr-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O BSKMOCNNLNDIMU-CDMKHQONSA-N 0.000 description 1
- BQMFWUKNOCJDNV-HJWJTTGWSA-N Phe-Val-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BQMFWUKNOCJDNV-HJWJTTGWSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241001040659 Plasmodium (Plasmodium) Species 0.000 description 1
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HFZNNDWPHBRNPV-KZVJFYERSA-N Pro-Ala-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HFZNNDWPHBRNPV-KZVJFYERSA-N 0.000 description 1
- ILMLVTGTUJPQFP-FXQIFTODSA-N Pro-Asp-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ILMLVTGTUJPQFP-FXQIFTODSA-N 0.000 description 1
- LUGOKRWYNMDGTD-FXQIFTODSA-N Pro-Cys-Asn Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O LUGOKRWYNMDGTD-FXQIFTODSA-N 0.000 description 1
- GURGCNUWVSDYTP-SRVKXCTJSA-N Pro-Leu-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GURGCNUWVSDYTP-SRVKXCTJSA-N 0.000 description 1
- DWGFLKQSGRUQTI-IHRRRGAJSA-N Pro-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 DWGFLKQSGRUQTI-IHRRRGAJSA-N 0.000 description 1
- JIWJRKNYLSHONY-KKUMJFAQSA-N Pro-Phe-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JIWJRKNYLSHONY-KKUMJFAQSA-N 0.000 description 1
- AJBQTGZIZQXBLT-STQMWFEESA-N Pro-Phe-Gly Chemical compound C([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 AJBQTGZIZQXBLT-STQMWFEESA-N 0.000 description 1
- IURWWZYKYPEANQ-HJGDQZAQSA-N Pro-Thr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IURWWZYKYPEANQ-HJGDQZAQSA-N 0.000 description 1
- AJJDPGVVNPUZCR-RHYQMDGZSA-N Pro-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1)O AJJDPGVVNPUZCR-RHYQMDGZSA-N 0.000 description 1
- ZYJMLBCDFPIGNL-JYJNAYRXSA-N Pro-Tyr-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1)C(O)=O ZYJMLBCDFPIGNL-JYJNAYRXSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 241000242677 Schistosoma japonicum Species 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- UCXDHBORXLVBNC-ZLUOBGJFSA-N Ser-Asn-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(O)=O UCXDHBORXLVBNC-ZLUOBGJFSA-N 0.000 description 1
- FIDMVVBUOCMMJG-CIUDSAMLSA-N Ser-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO FIDMVVBUOCMMJG-CIUDSAMLSA-N 0.000 description 1
- DOSZISJPMCYEHT-NAKRPEOUSA-N Ser-Ile-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O DOSZISJPMCYEHT-NAKRPEOUSA-N 0.000 description 1
- PMCMLDNPAZUYGI-DCAQKATOSA-N Ser-Lys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMCMLDNPAZUYGI-DCAQKATOSA-N 0.000 description 1
- QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
- FLONGDPORFIVQW-XGEHTFHBSA-N Ser-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FLONGDPORFIVQW-XGEHTFHBSA-N 0.000 description 1
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 1
- KKKVOZNCLALMPV-XKBZYTNZSA-N Ser-Thr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O KKKVOZNCLALMPV-XKBZYTNZSA-N 0.000 description 1
- DYEGLQRVMBWQLD-IXOXFDKPSA-N Ser-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CO)N)O DYEGLQRVMBWQLD-IXOXFDKPSA-N 0.000 description 1
- ZSDXEKUKQAKZFE-XAVMHZPKSA-N Ser-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N)O ZSDXEKUKQAKZFE-XAVMHZPKSA-N 0.000 description 1
- ODRUTDLAONAVDV-IHRRRGAJSA-N Ser-Val-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ODRUTDLAONAVDV-IHRRRGAJSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 1
- MPUMPERGHHJGRP-WEDXCCLWSA-N Thr-Gly-Lys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O MPUMPERGHHJGRP-WEDXCCLWSA-N 0.000 description 1
- UKINEYBQXPMOJO-UBHSHLNASA-N Trp-Asn-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N UKINEYBQXPMOJO-UBHSHLNASA-N 0.000 description 1
- FBVGQXJIXFZKSQ-GMVOTWDCSA-N Tyr-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N FBVGQXJIXFZKSQ-GMVOTWDCSA-N 0.000 description 1
- ADBDQGBDNUTRDB-ULQDDVLXSA-N Tyr-Arg-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O ADBDQGBDNUTRDB-ULQDDVLXSA-N 0.000 description 1
- NSTPFWRAIDTNGH-BZSNNMDCSA-N Tyr-Asn-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NSTPFWRAIDTNGH-BZSNNMDCSA-N 0.000 description 1
- NOOMDULIORCDNF-IRXDYDNUSA-N Tyr-Gly-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NOOMDULIORCDNF-IRXDYDNUSA-N 0.000 description 1
- CTDPLKMBVALCGN-JSGCOSHPSA-N Tyr-Gly-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O CTDPLKMBVALCGN-JSGCOSHPSA-N 0.000 description 1
- FMXFHNSFABRVFZ-BZSNNMDCSA-N Tyr-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O FMXFHNSFABRVFZ-BZSNNMDCSA-N 0.000 description 1
- TYFLVOUZHQUBGM-IHRRRGAJSA-N Tyr-Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 TYFLVOUZHQUBGM-IHRRRGAJSA-N 0.000 description 1
- FZSPNKUFROZBSG-ZKWXMUAHSA-N Val-Ala-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O FZSPNKUFROZBSG-ZKWXMUAHSA-N 0.000 description 1
- JIODCDXKCJRMEH-NHCYSSNCSA-N Val-Arg-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N JIODCDXKCJRMEH-NHCYSSNCSA-N 0.000 description 1
- FPCIBLUVDNXPJO-XPUUQOCRSA-N Val-Cys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(=O)NCC(O)=O FPCIBLUVDNXPJO-XPUUQOCRSA-N 0.000 description 1
- AGKDVLSDNSTLFA-UMNHJUIQSA-N Val-Gln-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N AGKDVLSDNSTLFA-UMNHJUIQSA-N 0.000 description 1
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 1
- BVWPHWLFGRCECJ-JSGCOSHPSA-N Val-Gly-Tyr Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N BVWPHWLFGRCECJ-JSGCOSHPSA-N 0.000 description 1
- NZGOVKLVQNOEKP-YDHLFZDLSA-N Val-Phe-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NZGOVKLVQNOEKP-YDHLFZDLSA-N 0.000 description 1
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
- QPJSIBAOZBVELU-BPNCWPANSA-N Val-Tyr-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N QPJSIBAOZBVELU-BPNCWPANSA-N 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229940027570 adenoviral vector vaccine Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- PERZMHJGZKHNGU-JGYWJTCASA-N bambermycin Chemical compound O([C@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H]([C@H](O1)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1NC(C)=O)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@H](O1)C(=O)NC=1C(CCC=1O)=O)O)C)[C@H]1[C@@H](OP(O)(=O)OC[C@@H](OC\C=C(/C)CC\C=C\C(C)(C)CCC(=C)C\C=C(/C)CCC=C(C)C)C(O)=O)O[C@H](C(O)=O)[C@@](C)(O)[C@@H]1OC(N)=O PERZMHJGZKHNGU-JGYWJTCASA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 108010060199 cysteinylproline Proteins 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 108010073628 glutamyl-valyl-phenylalanine Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 108010078274 isoleucylvaline Proteins 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明涉及AVC‑29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物。具体地,本发明提供AVC‑29或其药学上可接受的盐作为疫苗佐剂或者在制备疫苗佐剂中的用途、含有AVC‑29或其药学上可接受的盐的免疫原性或免疫刺激组合物及其制备方法和在制备疫苗中的用途。与传统的铝佐剂相比,AVC‑29在诱导抗体产生和细胞免疫应答方面,均具有显著优势。另外,AVC‑29安全性良好,可应用于多种类型的疫苗制剂,是潜在的理想的疫苗佐剂。
Description
技术领域
本发明涉及生物医药领域,具体涉及小分子化合物AVC-29作为疫苗佐剂或者在制备疫苗佐剂中的用途,含有AVC-29的免疫原性或免疫刺激组合物及其制备方法和在制备疫苗中的用途。
背景技术
疫苗接种是预防和控制传染性疾病最经济和最有效的措施,是应对新发、突发传染性疾病(如,新冠肺炎疫情)的有效手段。近年来依托现代生物技术和基因工程的迅猛发展,疫苗的研制取得了重大的进展。常用的疫苗种类包括灭活疫苗、重组亚单位疫苗、腺病毒载体疫苗、抗独特型抗体疫苗、核酸疫苗以及近年来新发展起来的多肽疫苗等。其中,灭活疫苗、重组亚单位疫苗以及多肽疫苗都存在蛋白或多肽抗原免疫原性弱,诱导的免疫保护力不足等缺陷。因此,需要加入佐剂来增强人体对抗原的适应性免疫应答强度,包含提升抗体和细胞免疫应答水平等,以诱导有效的免疫保护。另外,佐剂还可重塑人体对抗原的免疫应答类型,使疫苗能更有效地抵抗病原体。
铝盐佐剂是第一个被批准并普遍用于人类的疫苗佐剂,其作用机理是形成抗原贮藏库;产生颗粒性抗原来促进抗原提呈给免疫细胞;使抗原滞留,缓慢释放,从而吸引活性淋巴细胞,激活补体系统。该佐剂的优点是,安全性好,但缺陷是刺激的免疫反应较弱,特别是无法有效诱导细胞免疫应答。在开发针对某些胞内感染型病原体如结核分枝杆菌和带状疱疹病毒等时,铝盐佐剂效果很不理想。此外,铝盐佐剂还可能导致神经退行性疾病的发生。
在新型佐剂开发方面,欧美发达国家近几十年已取得较大发展,MF59佐剂、AS系列佐剂和CpG佐剂等都已在上市疫苗中使用。相比较而言,我国在这方面比较落后,亟需发展新型高效的疫苗佐剂。
随着研究者对于佐剂作用机制的深入研究和分子生物学的发展,人们将会更有针对性的选择合适的疫苗佐剂来预防和治疗疾病,而佐剂的应用也将会更加安全高效,但目前可供使用的人用佐剂并不多。因此开发研制新型的免疫佐剂有着重要的意义。
发明内容
发明人发现,小分子化合物AVC-29(结构如下文中所示)具有高效的疫苗佐剂效应。与传统的铝佐剂相比,AVC-29在诱导抗体产生和细胞免疫应答方面,均具有显著优势。另外,AVC-29安全性良好,可应用于多种类型的疫苗制剂,例如,用于针对SARS-CoV-2病毒的重组蛋白疫苗。因此,AVC-29小分子化合物是潜在的理想的疫苗佐剂。
因此,在第一个方面,本发明提供AVC-29或其药学上可接受的盐作为疫苗佐剂或者在制备疫苗佐剂中的用途,其中所述AVC-29结构如下所示:
在一些实施方案中,AVC-29或其药学上可接受的盐刺激受试者的免疫应答,例如,引发或增强受试者的免疫应答。在一些实施方案中,所述免疫应答为非特异性免疫应答。在一些实施方案中,所述免疫应答是抗原特异性免疫应答。在一些实施方案中,所述免疫应答包括B细胞的活化、T细胞的活化、抗体的产生和/或细胞因子的释放。
在另一个发面,本发明提供一种含有AVC-29或其药学上可接受的盐的免疫原性或免疫刺激组合物。
在一些实施方案中,所述免疫原性或免疫刺激组合物中进一步含有一种或多种抗原。在一些实施方案中,所述抗原为病原体的蛋白质、重组蛋白、糖蛋白、肽、多糖、脂质、脂多糖或核酸(包括DNA和mRNA)。在一些实施方案中,所述抗原衍生自细胞(例如,肿瘤细胞)、细菌或病毒。在一些实施方案中,所述抗原为SARS-CoV-2病毒抗原,所述SARS-CoV-2为新型冠状病毒,是由国际病毒分类学委员会(ICTV)命名的,又称为2019-nCoV。在一些实施方案中,所述抗原为SARS-CoV-2病毒的受体结合结构域抗原。在一些实施方案中,所述抗原具有如SEQ ID NO:1所示的氨基酸序列。
在一些实施方案中,所述免疫原性或免疫刺激组合物以单位剂量形式存在。在一些实施方案中,每单位剂量的免疫原性或免疫刺激组合物中含有0.1-500μg,优选1-100μg,更优选5-50μg的AVC-29或其药学上可接受的盐。所述单位剂量为临床使用的常规单次施用(注射)参考量。
在一些实施方案中,所述免疫原性或免疫刺激组合物中AVC-29或其药学上可接受的盐与抗原的质量比为(0.1-100):1、优选(0.1-10):1、更优选(0.5-5):1。
在一些实施方案中,所述免疫原性或免疫刺激组合物为可注射制剂、可吸入制剂或口服制剂形式,例如粉针剂、混悬剂、水针剂、喷雾剂、气雾剂、粉雾剂、粘贴片剂、舌下片剂或膜剂。
在一些实施方案中,所述免疫原性或免疫刺激组合物中还含有缓冲剂、等渗剂、防腐剂、稳定剂和增溶剂中的一种或多种,如糖(乳糖、蔗糖)、氨基酸(甘氨酸)、明胶和蛋白质(重组人血白蛋白)等。
在另一个方面,本发明进一步提供所述免疫原性或免疫刺激组合物的制备方法,其包括以下步骤:
将AVC-29或其药学上可接受的盐与抗原和任选地其它成分进行混合,优选地,在生理盐水中混合,得到所述免疫原性或免疫刺激组合物。
在另一个方面,本发明还提供所述的免疫原性或免疫刺激组合物用作疫苗或在制备疫苗中的用途。
在一些实施方案中,所述疫苗为灭活疫苗、减毒活疫苗或基因重组疫苗。所述疫苗可以是预防性的(即保护受试者免受所述疾病)或治疗性的(即帮助受试者抗击已感染的疾病)。在一些实施方案中,所述疫苗用于预防和/或治疗与所述抗原相关的疾病。在一些实施方案中,所述疾病为COVID-19(新型冠状病毒肺炎)。
在一些实施方案中,所述免疫原性或免疫刺激组合物刺激受试者的免疫应答,例如,引发或增强受试者的免疫应答。在一些实施方案中,所述免疫应答为非特异性免疫应答。在一些实施方案中,所述免疫应答是抗原特异性免疫应答。在一些实施方案中,所述免疫应答包括B细胞的活化、T细胞的活化、抗体的产生和/或细胞因子的释放。
在另一个方面,本发明提供一种刺激(例如,引发或增强)受试者免疫应答的方法,其包括向所述受试者施用有效量的所述免疫原性或免疫刺激组合物。
在一些实施方案中,所述免疫应答为非特异性免疫应答。在一些实施方案中,所述免疫应答是抗原特异性免疫应答。在一些实施方案中,所述免疫应答包括B细胞的活化、T细胞的活化、抗体的产生和/或细胞因子的释放。
在一些实施方案中,所述免疫原性或免疫刺激组合物的施用途径为口服、静脉内、皮内、经皮、经鼻、皮下或肛门。
在一些实施方案中,所述受试者为哺乳动物,例如人或非人类哺乳动物(包括但不限于狗、牛和马)。
术语定义
除非另有说明,否则本文中使用的科学和技术名词具有本领域技术人员所通常理解的含义。并且,本文中所用的细胞培养、分子遗传学、核酸化学、免疫学等实验室操作步骤均为相应领域内广泛使用的常规步骤。同时,为了更好地理解本发明的技术方案,下面提供相关术语的定义和解释。
术语“疫苗”是被施用以产生或人工增加对特定抗原的免疫的组合物。
术语“免疫原性组合物”、“免疫刺激组合物”是当施用于个体时能够在体内产生免疫应答的组合物。因此,应理解术语“免疫原性组合物”、“免疫刺激组合物”和“疫苗”是同义术语。在一些实施方案中,所述个体优选为哺乳动物,更优选为人,当然也可以是其它哺乳动物,例如所述组合物可在牛(cattle)(包括乳牛(cow))、绵羊、山羊或马中诱导免疫,或者宠物,如狗或猫。
因此,本文所述免疫原性组合物或免疫刺激组合为是这样一种组合物,其含有抗原并且能够产生针对这种抗原的免疫应答。产生的免疫应答可以是细胞(T细胞介导的)或体液(B细胞介导的,产生抗体)免疫应答。其也可以诱导细胞免疫应答和体液免疫应答。细胞免疫应答可以是CD8 T淋巴细胞介导的应答(即细胞毒性应答)或CD4 T淋巴细胞介导的应答(辅助性应答)。它也可以组合细胞毒性和辅助性细胞免疫应答。辅助性应答可涉及Th1、Th2或Th17淋巴细胞(这种淋巴细胞能够引发不同的细胞因子应答)。在一些实施方案中,本文所述组合物可显著刺激CD4 T细胞相应,特别是IFNγ、IL-2和IL-5细胞因子阳性的CD4 T细胞响应。
术语“疫苗佐剂”、“佐剂”是指能够修饰或增强对抗原的免疫应答的物质。换言之,针对抗原的免疫应答在佐剂存在时可以高于或不同于当佐剂不存在时(包括当应答被修饰时,例如,佐剂存在时活化的T细胞子集与不存在佐剂时活化的子集不同)。
术语“抗原”是为了使个体的免疫系统识别它而引发免疫应答的分子或分子的组合。这种抗原对于寻求免疫应答的宿主的机体而言可能是外来的。在这种情况下,抗原可以是由细菌或病毒表达的蛋白。抗原还可以是自身抗原,即由宿主细胞表达的蛋白,如肿瘤抗原。
抗原可以由死亡或未死亡的完整生物体(病毒或细菌、真菌、原生动物甚至癌细胞)、细胞(经辐射的或未经辐射的,经遗传修饰的或未经遗传修饰的)、或这些生物体或细胞的亚组分如细胞提取物或细胞裂解物所组成。抗原还可以由单分子如蛋白、重组蛋白、肽、多糖、脂质、糖脂、糖肽或其混合物组成。抗原也可以是通过化学修饰或稳定化进行修饰的以上列举的分子之一。
作为免疫原性或免疫刺激组合物中可以使用抗原的病原体的示例,包括感染性疾病的任何病原体(病毒、细菌、寄生虫、霉菌)。
对于感染性疾病,优选的病原体选自人免疫缺陷病毒(HIV)、甲型肝炎和乙型肝炎病毒、丙型肝炎病毒(HCV)、劳斯氏肉瘤病毒(RSV)、埃博拉病毒、巨细胞病毒、疱疹病毒、水痘带状疱疹病毒,爱泼斯坦-巴尔二氏病毒(Epstein Barr virus,EBV)、流感病毒、冠状病毒(例如,MERS、SARS、SARS-CoV-2,尤其是SARS-CoV-2)、腺病毒、轮状病毒、麻疹和风疹病毒、天花病毒、葡萄球菌(Staphylococcus)、衣原体(Chlamydiae)、结核分枝杆菌(Mycobacterium tuberculosis)、肺炎链球菌(Streptococcus pneumoniae)、炭疽芽孢杆菌(Bacillus anthracis)、霍乱弧菌(Vibrio cholerae)、幽门螺杆菌(HelicobacterPilorii)、沙门氏菌(Salmonella)、疟原虫(Plasmodium sp.)(恶性疟原虫(P.falciparum)、间日疟原虫(P.vivax)、卡氏肺囊虫(Pneumocystis carinii)、十二指肠贾第鞭毛虫(Giardiaduodenalis)、梨形鞭毛虫(Giardiose)、血吸虫(Schistosoma)、体吸虫病(Bilharziose)、曲霉(Aspergillus)、隐球菌(Cryptococcus)、白色念珠菌(Candidaalbicans)、单核细胞增多性李斯特氏菌(Listeria monocytogenes)或弓形虫(Toxoplasmagondii)。
作为可以受益于采用合适的抗原免疫的疾病的示例,包括但不限于癌症(良性或恶性肿瘤)、过敏、自身免疫疾病,如新型冠状病毒肺炎。
术语“药学上可接受的盐”包括AVC-29的酸加成盐及碱加成盐。例如钠盐、钾盐、钙盐、锂盐、葡甲胺盐、盐酸盐,氢澳酸盐,氢腆酸盐,硝酸盐,硫酸盐,硫酸氢盐,磷酸盐,磷酸氢盐,乙酸盐,丙酸盐,丁酸盐,草酸盐,三甲基乙酸盐,己二酸盐,藻酸盐,乳酸盐,柠檬酸盐,酒石酸盐,琥珀酸盐,马来酸盐,富马酸盐,苦味酸盐,天冬氨酸盐,葡糖酸盐,苯甲酸盐,甲磺酸盐,乙磺酸盐,苯磺酸盐,对甲苯磺酸盐或双羟萘酸盐等。
适合的盐的综述参见Stahl及Wermuth的“Handbook of Pharmaceutical Salts:Properties,Selection,and Use”(Wiley-VCH,2002)。用于制备可药用盐的方法为本领域技术人员已知的。
除非另有其它明确表示,否则在整个说明书和权利要求书中,术语“包括”或其变换如“包含”或“包括有”等等将被理解为包括所陈述的元件或组成部分,而并未排除其它元件或其它组成部分。
发明的有益效果
研究发现,小分子化合物AVC-29具有高效的疫苗佐剂效应。与传统的铝佐剂相比,AVC-29在诱导抗体产生和细胞免疫应答方面,均具有显著优势:
(1)血清SARS-CoV-2RBD特异性抗体滴度实验显示,AVC-29作为疫苗佐剂诱导抗体水平效应相较于Al佐剂高出近20倍;
(2)血清SARS-CoV-2中和抗体滴度实验显示,AVC-29作为疫苗佐剂诱导中和抗体水平相较于Al佐剂高出近10倍;
(3)相比传统Al佐剂,AVC-29佐剂可更强地刺激CD4 T细胞响应,特别是IFNγ、IL-2和IL-5细胞因子阳性的CD4 T细胞响应,由此可知,AVC-29佐剂可强效刺激抗原特异性T细胞免疫应答。
同时,AVC-29安全性良好,可应用于多种类型的疫苗制剂,例如,用于针对SARS-CoV-2病毒的重组蛋白疫苗。AVC-29小分子化合物是潜在的理想的疫苗佐剂。
附图说明
图1显示依据实施例2测定的使用AVC-29佐剂的OVA疫苗的OVA特异性IgG抗体滴度。
图2显示依据实施例5测定的使用AVC-29佐剂的SARS-CoV-2疫苗的SARS-CoV-2RBD抗原特异性IgG抗体滴度。
图3显示依据实施例6测定的使用AVC-29佐剂的SARS-CoV-2疫苗的真病毒中和抗体滴度。
图4显示依据实施例7测定的使用本发明AVC-29佐剂的SARS-CoV-2疫苗诱导的细胞因子阳性的CD4 T细胞免疫应答。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将结合实施例对本发明进行清楚、完整地描述。显然,所公开的实施例是本发明一部分实施例,而非全部。基于所公开的实施例,本领域普通技术人员在没有作出创造性劳动前提下所进行的修改和替换,都属于本发明保护的范围。
另外,为了更好地说明本发明,在下文的实施例中给出了众多的具体实验细节。本领域技术人员应当理解,没有某些具体细节,本发明同样可以实施。在实施例中,对于本领域技术人员熟知的原料、元件、方法、手段等未作详细描述,以便于凸显本发明的主旨。
实施例1:模式抗原OVA的疫苗制备
试剂来源:
卵白蛋白OVA,购自Sigma;
铝(Al)佐剂,购自美国Thermo Fisher公司;
AVC-29购自安博公司。
将OVA蛋白抗原分别与AVC-29佐剂、铝佐剂一起溶于生理盐水,涡旋混匀,以配制疫苗,所得疫苗分别称为OVA-AVC-29和OVA-铝。
按照如下组别分别免疫小鼠:
生理盐水组;
单独的Al佐剂组(铝佐剂,50μl);
单独的AVC-29佐剂组(AVC-29,5μg);
单独的OVA抗原组(OVA,5μg);
OVA-Al组(OVA,5μg;铝佐剂,50μl);和
OVA-AVC-29组(OVA和AVC-29佐剂各5μg);
上述各组中,括号中显示了每剂疫苗的抗原或佐剂含量,每剂疫苗体积为100μl。
免疫小鼠的程序如下:
按照上述疫苗组别,分别对6-8周龄雌性BALB/c小鼠进行免疫,每组6只小鼠。每只小鼠分别在第0天和第14天进行两针疫苗免疫,免疫方式为大腿肌肉注射,每次疫苗注射体积为100μl。第28天,对小鼠处死,采血,4℃分离血清,并于56℃灭活30分钟,然后保存于-80℃待用。
实施例2:血清OVA特异性抗体滴度测定
对于实施例1所得免疫小鼠血清,通过ELISA方法测定其血清OVA特异性抗体滴度。具体步骤如下:将OVA蛋白用ELISA包被液稀释至1μg/ml,96孔板每孔加入100μl,4℃放置过夜。第二天封闭ELISA板,小鼠血清按照2倍梯度稀释,加入到ELISA板中37℃孵育1小时,之后用含0.05%吐温20的PBS(PBST)清洗三次后,加入羊抗鼠HRP二抗(购自北京中杉金桥生物技术公司),37℃孵育1小时后,PBST清洗三次,加入TMB显色液显示,并用2M盐酸终止,在酶标仪上于OD450处读值。
结果如图1所示,图1结果显示:单独使用OVA抗原组诱导的抗体滴度为约68;OVA-Al组和OVA-AVC-29组诱导的抗体滴度比单独使用OVA抗原组分别提升了约13倍和160倍;由此可见,用AVC-29佐剂配制的疫苗所诱导的抗体滴度显著高于使用传统铝佐剂的疫苗。
实施例3:SARS-CoV-2RBD抗原的表达纯化
本申请的发明人采用发明专利申请号CN202010581414.3中记载的RBD二聚体构建物作为抗原,所述抗原具有如SEQ ID NO:1所示的氨基酸序列,并且由如SEQ ID NO:2所示(对应于CN202010581414.3中的SEQ ID NO:20)的核苷酸序列编码。
SEQ ID NO:1:
SEQ ID NO:2:
在SEQ ID NO:2所示核苷酸序列的5’端加上编码MERS S蛋白自身信号肽(MIHSVFLLMFLLTPTES;SEQ ID NO:3)的核苷酸序列(ATGATCCACT CAGTGTTTCT CTTAATGTTTCTACTAACTC CCACGGAGTC G;SEQ ID NO:4),在其3’端加上编码6个组氨酸的核苷酸序列后,再加上终止密码子;将如此所得核苷酸序列插入到载体pCAGGS中的EcoRI和XhoI酶切位点,其起始密码子上游有Kozak序列gccacc。
将如上所得质粒体转染293T细胞,之后收获上清。将细胞上清通过0.22μm孔径的滤膜过滤,除去细胞碎片。将细胞培养上清挂镍亲和柱(Histrap),4度过夜。以缓冲液A(20mM Tris,150mM NaCl,pH8.0)洗脱柱子,以去除非特异结合蛋白。最后,目的蛋白以缓冲液(20mM Tris,150mM NaCl,pH 8.0,300mM咪唑)从柱子洗脱下来,并以10K截留(10cutoff)浓缩管将洗脱液浓缩至5ml以内。再通过Superdex 200Hi load 16/60柱子(GE)进行分子筛层析,以进行进一步的目的蛋白纯化。分子筛层析缓冲液为PBS。经过分子筛层析,在洗脱体积80ml处出现唯一主峰,将其收集浓缩后,-80℃保存。
实施例4:SARS-CoV-2RBD抗原免疫小鼠实验
将实施例3中获得的SARS-CoV-2RBD抗原分别与AVC-29佐剂、铝佐剂一起溶于生理盐水,涡旋混匀,以配制疫苗,所得疫苗分别称为RBD-AVC-29和RBD-铝。
按照如下组别分别免疫小鼠:
生理盐水组;
单独的Al佐剂组(铝佐剂,50μl);
单独的AVC-29佐剂组(AVC-29,5μg);
RBD-Al组(RBD抗原,5μg;铝佐剂,50μl);和
RBD-AVC-29组(RBD抗原和AVC-29佐剂各5μg);
上述各组中,括号中显示了每剂疫苗的抗原或佐剂含量,每剂疫苗体积为100μl。
免疫小鼠的程序如下:
使用生理盐水或疫苗,对6-8周龄雌性BALB/c小鼠进行免疫,每组6只小鼠。每只小鼠分别在第0天和第14天进行两针疫苗免疫,免疫方式为大腿肌肉注射,每次疫苗注射体积为100μl。第28天,对小鼠处死,采集血液和脾脏;对于血液,于4℃分离血清,然后于56℃灭活30分钟,之后保存于-80℃待用;脾脏的处理方法见以下实施例7。
实施例5:血清SARS-CoV-2RBD特异性抗体滴度测定
对于实施例4所得免疫小鼠血清,通过ELISA方法测定其血清RBD特异性抗体滴度。具体步骤如下:将SARS-CoV-2RBD二聚体蛋白用ELISA包被液稀释至1μg/ml,96孔板每孔加入100μl,4℃放置过夜。第二天封闭ELISA板,小鼠血清按照2倍梯度稀释,加入到ELISA板中37℃孵育1小时,之后用含0.05%吐温20的PBS(PBST)清洗三次后,加入羊抗鼠HRP二抗(购自北京中杉金桥生物技术公司),37℃孵育1小时后,PBST清洗三次,加入TMB显色液显示,并用2M盐酸终止,在酶标仪上于OD450处读值。
结果如图2显示,图2结果显示:RBD-Al免疫组的血清抗原特异性抗体滴度约1.1*105,而RBD-AVC-29疫组的血清抗原特异性抗体滴度可达1.9*106;这表明,AVC-29作为疫苗佐剂诱导抗体水平的效应显著高于传统的铝佐剂。
实施例6:血清SARS-CoV-2中和抗体滴度测定
使用基于细胞病变效应(CPE)的微量中和实验,测定实施例4所得免疫小鼠血清的SARS-CoV-2真病毒中和抗体滴度。具体步骤如下:
将实施例4所得免疫小鼠的血清按2倍比进行梯度稀释,将稀释后血清与100TCID50野生型SARS-CoV-2真病毒(HB01株,保存于中国科学院微生物研究所P3实验室)等体积混合,37℃孵育1小时后,向100μl混合液中加入100μl密度为1.5×105个/mL的Vero E6细胞。37℃孵育72小时后,显微镜下观察细胞的病变情况。最后,通过Karber法计算保护50%的细胞免受病毒感染时的血清稀释倍数,即为真病毒中和抗体滴度NT50值。
结果如图3所示,图3结果显示:在生理盐水组、单独Al佐剂组和单独AVC-29佐剂组免疫小鼠血清中,均未观察到针对SARS-CoV-2真病毒的中和抗体;而对于RBD-Al组和RBD-AVC-29组免疫小鼠,显示它们所诱导的中和抗体滴度分别达498和4469,即,RBD-AVC-29组比RBD-Al组所诱导的中和抗体水平高近10倍。
实施例7:SARS-CoV-2疫苗诱导的细胞免疫反应评价
脾脏处理:将实施例4所得免疫小鼠的脾脏放置于预冷的1640培养基中。将40μm筛网放在50ml离心管上,使用5ml注射器推头研磨脾脏,之后加1640培养基使细胞滴进50ml管中,过滤掉杂质及大的细胞团。把所有细胞转移到15ml离心管中,室温2000rpm离心收集细胞,再加入12ml的1640培养基清洗一遍,再次离心,收集细胞。向收集的细胞团块中,加入4ml的红细胞裂解液,悬浮细胞,室温放置5-10分钟,再加入8ml的1640培养基,离心,收集细胞;加入12ml 1640培养基清洗一遍,再次离心,收集细胞。加入10ml的1640培养基,悬浮细胞,使用细胞计数板计算细胞总数。再次离心,收集细胞;向收集的细胞团块中,加入一定体积的10%FBS1640培养基,使细胞浓度为1×107个/ml。
胞内细胞因子染色实验:在圆底96孔板中,向每孔加入1×106个上述所得小鼠脾脏细胞,然后加入RBD多肽库(每条多肽的终浓度为2μg/ml)刺激细胞,分别设置加入植物血凝素(PHA)刺激的组为阳性对照组,不加任何刺激物的组为阴性对照组。刺激4小时后,加入莫奈霉素GolgiStop(购自BD Bioscience),接着在细胞培养箱中培养12小时后,离心收集细胞。然后,使用PE标记的抗鼠CD3抗体,FITC标记的抗鼠CD4抗体,APC-Cy7标记的抗鼠CD8抗体,BV605标记的抗鼠IL-2抗体,BB700标记的抗鼠TNFα抗体,BV421标记的抗鼠IFNγ抗体,BV786标记的抗鼠IL-4抗体和APC标记的抗鼠IL-5抗体(所有抗体全部购自Biolegend公司),对细胞进行抗体染色,其中操作步骤完全按照BD公司Cytofix/CytopermTMFixation/Permeabilization试剂盒说明书和抗体使用说明书操作。然后,在FACSCanton流式细胞仪上检测细胞荧光。
各细胞因子阳性的CD4 T细胞的荧光检测统计结果如图4所示,图4结果表明:相比传统Al佐剂,AVC-29佐剂可更强地刺激CD4 T细胞响应,特别是IFNγ、IL-2和IL-5细胞因子阳性的CD4 T细胞响应,由此可知,AVC-29佐剂可强效刺激抗原特异性T细胞免疫应答。
最后应说明的是,以上实施例仅用以说明本发明的技术方案,而非对其限制。尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各技术方案的精神和范围。
SEQUENCE LISTING
<110> 海南大学
<120> AVC-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物
<130> IDC210218
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 438
<212> PRT
<213> artificial
<400> 1
Arg Val Gln Pro Thr Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn
1 5 10 15
Leu Cys Pro Phe Gly Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val
20 25 30
Tyr Ala Trp Asn Arg Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser
35 40 45
Val Leu Tyr Asn Ser Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val
50 55 60
Ser Pro Thr Lys Leu Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp
65 70 75 80
Ser Phe Val Ile Arg Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln
85 90 95
Thr Gly Lys Ile Ala Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr
100 105 110
Gly Cys Val Ile Ala Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly
115 120 125
Gly Asn Tyr Asn Tyr Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys
130 135 140
Pro Phe Glu Arg Asp Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr
145 150 155 160
Pro Cys Asn Gly Val Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser
165 170 175
Tyr Gly Phe Gln Pro Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val
180 185 190
Val Val Leu Ser Phe Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly
195 200 205
Pro Lys Lys Ser Thr Asn Leu Val Lys Asn Lys Arg Val Gln Pro Thr
210 215 220
Glu Ser Ile Val Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly
225 230 235 240
Glu Val Phe Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg
245 250 255
Lys Arg Ile Ser Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser
260 265 270
Ala Ser Phe Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu
275 280 285
Asn Asp Leu Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe Val Ile Arg
290 295 300
Gly Asp Glu Val Arg Gln Ile Ala Pro Gly Gln Thr Gly Lys Ile Ala
305 310 315 320
Asp Tyr Asn Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys Val Ile Ala
325 330 335
Trp Asn Ser Asn Asn Leu Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr
340 345 350
Leu Tyr Arg Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp
355 360 365
Ile Ser Thr Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys Asn Gly Val
370 375 380
Glu Gly Phe Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro
385 390 395 400
Thr Asn Gly Val Gly Tyr Gln Pro Tyr Arg Val Val Val Leu Ser Phe
405 410 415
Glu Leu Leu His Ala Pro Ala Thr Val Cys Gly Pro Lys Lys Ser Thr
420 425 430
Asn Leu Val Lys Asn Lys
435
<210> 2
<211> 1314
<212> DNA
<213> artificial
<400> 2
agagtgcaac ctacagaatc aatcgtgaga tttcctaaca tcacaaacct ttgccctttc 60
ggcgaggtgt ttaacgcaac aagatttgca tcagtgtacg catggaacag aaagcgtata 120
tcaaactgcg tggcagatta ctcagtgctt tacaactcag catcattcag tacgtttaaa 180
tgctacggag tgtcacctac aaagctaaat gatctttgct ttacaaacgt gtacgcagat 240
tcatttgtga tcagaggaga tgaagtgaga caaatcgcac ctggacaaac aggaaagatt 300
gccgattaca actacaaact tcctgatgat ttcaccggct gcgtgatcgc atggaactca 360
aacaaccttg attcaaaggt aggtggtaat tataattatt tgtataggct ctttcgtaag 420
agcaacttaa agccatttga gcgagatatc tcaacagaaa tctaccaagc aggatcaaca 480
ccttgcaacg gagtggaagg atttaactgc tactttcctc ttcaatcata cggatttcaa 540
cctacaaacg gagtgggata ccaaccttac agagtggtgg tgctttcatt tgaacttctt 600
cacgcacctg caacagtgtg cggacctaag aagagcacga accttgtgaa gaataagaga 660
gtgcaaccta cagaatcaat cgtgagattt cctaacatca caaacctttg ccctttcggc 720
gaggtgttta acgcaacaag atttgcatca gtgtacgcat ggaacagaaa gcgtatatca 780
aactgcgtgg cagattactc agtgctttac aactcagcat cattcagtac gtttaaatgc 840
tacggagtgt cacctacaaa gctaaatgat ctttgcttta caaacgtgta cgcagattca 900
tttgtgatca gaggagatga agtgagacaa atcgcacctg gacaaacagg aaagattgcc 960
gattacaact acaaacttcc tgatgatttc accggctgcg tgatcgcatg gaactcaaac 1020
aaccttgatt caaaggtagg tggtaattat aattatttgt ataggctctt tcgtaagagc 1080
aacttaaagc catttgagcg agatatctca acagaaatct accaagcagg atcaacacct 1140
tgcaacggag tggaaggatt taactgctac tttcctcttc aatcatacgg atttcaacct 1200
acaaacggag tgggatacca accttacaga gtggtggtgc tttcatttga acttcttcac 1260
gcacctgcaa cagtgtgcgg acctaagaag agcacgaacc ttgtgaagaa taag 1314
Claims (10)
2.权利要求1所述的免疫原性或免疫刺激组合物,其进一步含有一种或多种抗原;
优选地,所述抗原为病原体的蛋白质、重组蛋白、糖蛋白、肽、多糖、脂质、脂多糖或核酸(包括DNA和mRNA);
优选地,所述抗原衍生自细胞(例如,肿瘤细胞)、细菌或病毒;
优选地,所述抗原为SARS-CoV-2病毒抗原;
优选地,所述抗原为SARS-CoV-2病毒的受体结合结构域抗原;
优选地,所述抗原具有如SEQ ID NO:1所示的氨基酸序列。
3.权利要求1或2所述的免疫原性或免疫刺激组合物,其以单位剂量形式存在;
优选地,每单位剂量的免疫原性或免疫刺激组合物中含有0.1-500μg,优选1-100μg,更优选5-50μg的AVC-29或其药学上可接受的盐。
4.根据权利要求1-3任一项所述的免疫原性或免疫刺激组合物,其中AVC-29或其药学上可接受的盐与抗原的质量比为(0.1-100):1、优选(0.1-10):1、更优选(0.5-5):1。
5.根据权利要求1-4任一项所述的免疫原性或免疫刺激组合物,其为可注射制剂、可吸入制剂或口服制剂形式,例如粉针剂、混悬剂、水针剂、喷雾剂、气雾剂、粉雾剂、粘贴片剂、舌下片剂或膜剂;
优选地,所述免疫原性或免疫刺激组合物中还含有缓冲剂、等渗剂、防腐剂、稳定剂和增溶剂中的一种或多种。
6.根据权利要求1-5任一项所述的免疫原性或免疫刺激组合物的制备方法,其包括以下步骤:
将AVC-29或其药学上可接受的盐与抗原和任选地其它成分进行混合,优选地,在生理盐水中混合,得到所述免疫原性或免疫刺激组合物。
7.AVC-29或其药学上可接受的盐作为疫苗佐剂或者在制备疫苗佐剂中的用途。
8.权利要求1-5任一项所述的免疫原性或免疫刺激组合物用作疫苗或在制备疫苗中的用途。
9.权利要求7或8的用途,其中所述疫苗为灭活疫苗、减毒活疫苗或基因重组疫苗;
优选地,所述疫苗为预防性或治疗性疫苗;
优选地,所述疫苗用于预防和/或治疗与所述抗原相关的疾病;
优选地,所述疾病为COVID-19(新型冠状病毒肺炎)。
10.权利要求7-9任一项所述的用途,其中所述AVC-29或其药学上可接受的盐、或免疫原性或免疫刺激组合物刺激(例如,引发或增强)受试者的免疫应答;
优选地,所述免疫应答为非特异性免疫应答;
优选地,所述免疫应答是抗原特异性免疫应答;
优选地,所述免疫应答包括B细胞的活化、T细胞的活化、抗体的产生和/或细胞因子的释放。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110779345.1A CN113476600B (zh) | 2021-07-09 | 2021-07-09 | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 |
PCT/CN2022/104620 WO2023280303A1 (zh) | 2021-07-09 | 2022-07-08 | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110779345.1A CN113476600B (zh) | 2021-07-09 | 2021-07-09 | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113476600A true CN113476600A (zh) | 2021-10-08 |
CN113476600B CN113476600B (zh) | 2023-05-30 |
Family
ID=77937755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110779345.1A Active CN113476600B (zh) | 2021-07-09 | 2021-07-09 | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113476600B (zh) |
WO (1) | WO2023280303A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023280303A1 (zh) * | 2021-07-09 | 2023-01-12 | 海南大学 | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105903009A (zh) * | 2016-04-05 | 2016-08-31 | 中国科学院过程工程研究所 | 一种基于阿拉伯半乳聚糖-聚肌苷酸胞苷酸修饰的结核分枝杆菌亚单位疫苗及其制备方法 |
CN106459058A (zh) * | 2014-05-01 | 2017-02-22 | 诺华股份有限公司 | 作为toll‑样受体7激动剂的化合物和组合物 |
CN111217917A (zh) * | 2020-02-26 | 2020-06-02 | 康希诺生物股份公司 | 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法 |
CN111592602A (zh) * | 2020-02-10 | 2020-08-28 | 中国科学院微生物研究所 | 一种β冠状病毒抗原、其制备方法和应用 |
CN111892648A (zh) * | 2020-06-08 | 2020-11-06 | 中国科学院上海药物研究所 | 偶联tlr7激动剂的新型冠状病毒多肽疫苗及其应用 |
CN112220920A (zh) * | 2020-10-30 | 2021-01-15 | 上海泽润生物科技有限公司 | 一种重组新型冠状病毒疫苗组合物 |
WO2021130195A1 (en) * | 2019-12-24 | 2021-07-01 | F. Hoffmann-La Roche Ag | Method of treating virus infection using a tlr7 agonist |
WO2022059023A1 (en) * | 2020-09-15 | 2022-03-24 | Bharat Biotech International Limited | Toll-like receptor (tlr) agonist vaccine formulation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113476600B (zh) * | 2021-07-09 | 2023-05-30 | 海南大学 | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 |
-
2021
- 2021-07-09 CN CN202110779345.1A patent/CN113476600B/zh active Active
-
2022
- 2022-07-08 WO PCT/CN2022/104620 patent/WO2023280303A1/zh unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106459058A (zh) * | 2014-05-01 | 2017-02-22 | 诺华股份有限公司 | 作为toll‑样受体7激动剂的化合物和组合物 |
CN105903009A (zh) * | 2016-04-05 | 2016-08-31 | 中国科学院过程工程研究所 | 一种基于阿拉伯半乳聚糖-聚肌苷酸胞苷酸修饰的结核分枝杆菌亚单位疫苗及其制备方法 |
WO2021130195A1 (en) * | 2019-12-24 | 2021-07-01 | F. Hoffmann-La Roche Ag | Method of treating virus infection using a tlr7 agonist |
CN111592602A (zh) * | 2020-02-10 | 2020-08-28 | 中国科学院微生物研究所 | 一种β冠状病毒抗原、其制备方法和应用 |
CN111217917A (zh) * | 2020-02-26 | 2020-06-02 | 康希诺生物股份公司 | 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法 |
CN111892648A (zh) * | 2020-06-08 | 2020-11-06 | 中国科学院上海药物研究所 | 偶联tlr7激动剂的新型冠状病毒多肽疫苗及其应用 |
WO2022059023A1 (en) * | 2020-09-15 | 2022-03-24 | Bharat Biotech International Limited | Toll-like receptor (tlr) agonist vaccine formulation |
CN112220920A (zh) * | 2020-10-30 | 2021-01-15 | 上海泽润生物科技有限公司 | 一种重组新型冠状病毒疫苗组合物 |
Non-Patent Citations (4)
Title |
---|
ATHINA ANGELOPOULOU,等: "Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19", 《ENVIRONMENTAL RESEARCH》 * |
HALEY A PARTLOW,等: "The comparison of two SARS-CoV-2 spike protein antigens in TLRadjuvanted subunit vaccines", 《THE JOURNAL OF IMMUMOLOGY》 * |
QINGRUI HUANG,等: "A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2", 《NATURE COMMUNICATIONS》 * |
史瑞,等: "抗新型冠状病毒单克隆中和抗体药物研发进展", 《中国生物工程杂志》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023280303A1 (zh) * | 2021-07-09 | 2023-01-12 | 海南大学 | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN113476600B (zh) | 2023-05-30 |
WO2023280303A1 (zh) | 2023-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ghaffarifar | Plasmid DNA vaccines: where are we now | |
ES2350043T3 (es) | Composiciones para producir, incrementar y mantener las respuestas inmunes contra epítopos restringidos de mhc de clase i, con fines profilácticos o terapéuticos. | |
JPH07504683A (ja) | Gm−csfのワクチンアジュバントとしての利用 | |
AU2005215020A1 (en) | System immune activation method using non CpG nucleic acids | |
WO1999061068A9 (en) | Anti-prostate cancer vaccines, and methods of making, using and evaluating the same | |
Yoon et al. | Cytokine GM‐CSF genetic adjuvant facilitates prophylactic DNA vaccine against pseudorabies virus through enhanced immune responses | |
CA2453959A1 (en) | Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres | |
CN113476600A (zh) | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 | |
EP1706140A1 (en) | Methods for tailoring the immune response to an antigen or immunogen | |
JP5901084B2 (ja) | ペプチドアジュバント | |
ES2546301T3 (es) | Composición que contiene Leishmania Lip2a | |
US20040146485A1 (en) | Vaccines including as an adjuvant type 1 ifn and process related thereto | |
AU2002309245A1 (en) | Vaccines including as an adjuvant type 1 IFN and processes related thereto | |
JP2002520299A (ja) | ポリヌクレオチドワクチン配合物 | |
Zarrati et al. | Humoral immune responses in DNA vaccine formulated with poly [methyl methacrylate] against Leishmania major | |
RU2294212C2 (ru) | Вакцинный состав, потенцированный комбинацией днк и антигена | |
EP1371375B1 (en) | Vaccine to protect animals against leishmania | |
US8986711B2 (en) | Vaccine to protect animals against leishmania | |
CN115948447A (zh) | 重组真核表达载体pVAX-LAMP-CCHFV-NP、构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240104 Address after: Room 303-18, 3rd Floor, Building 6, Zone 1, No. 8 Life Park Road, Life Science Park, Changping District, Beijing, 102299 Patentee after: Beijing Baiyi Wuyou Technology Development Co.,Ltd. Address before: 570228 No. 58 Renmin Road, Hainan, Haikou Patentee before: HAINAN University |
|
TR01 | Transfer of patent right |